Pacific Biosciences of California, Inc. (PACB)
| Market Cap | 6.84B |
| Revenue (ttm) | 78.89M |
| Net Income (ttm) | 29.40M |
| Shares Out | 165.19M |
| EPS (ttm) | 0.17 |
| PE Ratio | 207.18 |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 1 |
| Last Price | $35.22 |
| Previous Close | $30.57 |
| Change ($) | 4.65 |
| Change (%) | 15.21% |
| Day's Open | 32.69 |
| Day's Range | 31.84 - 35.69 |
| Day's Volume | 6,072,463 |
| 52-Week Range | 2.20 - 53.69 |
MENLO PARK, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) announced today that its executives will be speaking at the following investor conf...
The battle against Covid-19 is about to get uglier. Coronavirus mutations threaten to undercut a year's worth of work upholding Covid stocks like Pfizer, Moderna and Regeneron Pharmaceuticals.
The battle against Covid-19 is about to get uglier. Coronavirus mutations threaten to undercut a year's worth of work upholding Covid stocks like Pfizer, Moderna and Regeneron Pharmaceuticals.
Pacific Biosciences' (PACB) Sequel II HiFi sequencing gets utilized by LabCorp to detect SARS-COV-2 variants in the United States.
The stock price of Pacific Biosciences of California a biotechnology company that develops gene sequencing systems, has seen a solid 27% rise over the last ten trading days, though it's down 4...
Labcorp Using PacBio's HiFi Sequencing to Detect SARS-CoV-2 Variants in the U.S. Labcorp Using PacBio's HiFi Sequencing to Detect SARS-CoV-2 Variants in the U.S.
Will SoftBank Group Corp.'s (SFTBY) huge investment in Pacific Biosciences of California Inc.(NASDAQ:PACB) turn out to be another home run for the Japanese conglomerate or will it be a swing a...
Pacific Biosciences (PACB) suffers a Product revenue decline in the fourth quarter.
ESSA Pharma Inc. (NASDAQ: EPIX) shares are trading higher after the company reported first-quarter earnings results and highlighted the presentation of Phase 1 pharmacology data of EPI-7386 fo...
With the trading day more than halfway over, the broad markets were trading sideways on Thursday.
The pandemic didn't weigh on the genetic sequencing systems company nearly as much as earlier in 2020.
The gene sequencing company is receiving a $900 million investment from a renowned international conglomerate.
The gene sequencing company is receiving a $900 million investment from a renowned international conglomerate.
Pacific Biosciences (PACB) delivered earnings and revenue surprises of -102.33% and -0.05%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for ...
Shares of Pacific Biosciences (NASDAQ:PACB) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 0.00% over the past year to $0.37, ...
MENLO PARK, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31...
Pacific Biosciences is getting an investment from a holding company.
MENLO PARK, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (the “Company”), a leading provider of high-quality, long-read sequencing platforms...
SoftBank Group Corp (OTCMKTS: SFTBY) will reportedly invest $900 million into Pacific Biosciences of California Inc (NASDAQ: PACB), according to the Wall Street Journal, which comes on top of ...
Pacific Biosciences' (PACB) fourth-quarter results are likely to reflect strength in its Sequel system.
On Wednesday, February 10, Pacific Biosciences (NASDAQ:PACB) will release its latest earnings report. Check out Benzinga's preview to understand the implications.
MENLO PARK, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequen...
A new leadership team is betting that it can make long-read genome sequencing more competitive.
MENLO PARK, Calif., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequen...
MENLO PARK, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its fourth quarter 2020 financia...
After a large 13x rise since the March 23 levels of last year, at the current price of around $36 per share we believe Pacific Biosciences of California stock, a biotechnology company that dev...
Investor confidence is high on Pacific Biosciences (PACB) stock, courtesy of solid prospects.
Pacific Biosciences' (PACB) preliminary Q420 revenues are expected to improve from Q320.
New platform expected to make whole genome sequencing significantly more affordable and accessible for use in mainstream medical care New platform expected to make whole genome sequencing sign...
MENLO PARK, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality, long ...
MENLO PARK, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (the “Company”) (NASDAQ: PACB), a leading provider of high-quality sequencing platforms, today ann...
MENLO PARK, Calif., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leading provider of high-quality sequencing solutions, today announced the appoi...
Seven new Sequel IIe Systems will support expanded generation of high-quality genomes for improving fundamental understanding of biology and aiding biodiversity conservation Seven new Sequel I...
Due to the persistence of global manufacturing and supply-chain disruptions and a few other hostile externalities, three stocks are likely to register a dull 2021 performance.
Investors need to pay close attention to Pacific Biosciences (PACB) stock based on the movements in the options market lately.
MENLO PARK, Calif., Dec. 18, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequen...
BioCardia (NASDAQ: BCDA) shares are trading higher. The company said it anticipates data safety monitoring board verbal feedback by the end of Dec. 15 for its pivotal Phase 3 CardiAMP Heart Fa...
Investor confidence is high on Pacific Biosciences (PACB) stock, courtesy of its solid prospects.
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock?
MENLO PARK, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) (“Pacific Biosciences” or the “Company”) today announced that it has priced its pre...
MENLO PARK, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) today announced that it intends to offer and sell $85.0 million of shares of its co...
Pacific Biosciences (PACB) saw revenue decline in both its operating segments in the third quarter.
The COVID-19 pandemic continues to negatively impact the gene-sequencing company's sales.
Pacific Biosciences of California, Inc. (PACB) CEO Christian Henry on Q3 2020 Results - Earnings Call Transcript
Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0.00% and -6.46%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for th...
MENLO PARK, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its third quarter ended September 30, 2020.
Several medical product stocks have come up with bullish earnings reports so far this reporting cycle. Let's see how STE, HSIC, PACB, INSP are poised ahead of their announcements.
Pacific Biosciences (PACB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MENLO PARK, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its Third Quarter 2020 Financial...
Pacific Biosciences' (PACB) recently-launched Sequel IIe System is powered by its SMRT technology.
About PACB
Pacific Biosciences of California designs, develops, and manufactures sequencing systems to resolve genetically complex problems. Its single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. The company also provides consumable products, including SMRT cells, as well as various reagent kits designed for specific workflow such as template preparation to convert DNA into SMRTbell double-stranded DNA library formats including molecular biology reagents, such as ligase, buffers and ... [Read more...]
| Industry Diagnostics & Research | IPO Date Oct 27, 2010 |
| CEO Christian O. Henry M.B.A. | |
| Stock Exchange NASDAQ | Ticker Symbol PACB |
Analyst Forecasts
According to 5 analysts, the average rating for PACB stock is "Buy." The 12-month stock price forecast is 51.50, which is an increase of 46.22% from the latest price.